Neovascularization and functional recovery after intracerebral hemorrhage is conditioned by the Tp53 Arg72Pro single-nucleotide polymorphism by Rodríguez, Cristina et al.
OPEN
Neovascularization and functional recovery after
intracerebral hemorrhage is conditioned by the Tp53
Arg72Pro single-nucleotide polymorphism
Cristina Rodríguez1,2, Tomás Sobrino3, Jesús Agulla1,2, Verónica Bobo-Jiménez1,2, María E Ramos-Araque1,2, Juan J Duarte1,
José C Gómez-Sánchez1, Juan P Bolaños1,2, José Castillo3 and Ángeles Almeida*,1,2
Intracerebral hemorrhage (ICH) is a devastating subtype of stroke that lacks effective therapy and reliable prognosis.
Neovascularization following ICH is an essential compensatory response that mediates brain repair and modulates the clinical
outcome of stroke patients. However, the mechanism that dictates this process is unknown. Bone marrow-derived endothelial
progenitor cells (EPCs) promote endothelial repair and contribute to ischemia-induced neovascularization. The human Tp53 gene
harbors a common single-nucleotide polymorphism (SNP) at codon 72, which yields an arginine-to-proline amino-acidic
substitution (Arg72Pro) that modulates the apoptotic activity of the p53 protein. Previously, we found that this SNP controls
neuronal susceptibility to ischemia-induced apoptosis in vitro. Here, we evaluated the impact of the Tp53 Arg72Pro SNP on
vascular repair and functional recovery after ICH. We first analyzed EPC mobilization and functional outcome based on the
modified Rankin scale scores in a hospital-based cohort of 78 patients with non-traumatic ICH. Patients harboring the Pro allele of
the Tp53 Arg72Pro SNP showed higher levels of circulating EPC-containing CD34+ cells, EPC-mobilizing cytokines – vascular
endothelial growth factor and stromal cell-derived factor-1α – and good functional outcome following ICH, when compared with
the homozygous Arg allele patients, which is compatible with increased neovascularization. To assess directly whether Tp53
Arg72Pro SNP regulated neovascularization after ICH, we used the humanized Tp53 Arg72Pro knock-in mice, which were subjected
to the collagenase-induced ICH. The brain endothelial cells of the Pro allele-carrying mice were highly resistant to ICH-mediated
apoptosis, which facilitated cytokine-mediated EPC mobilization, cerebrovascular repair and functional recovery. However, these
processes were not observed in the Arg allele-carrying mice. These results reveal that the Tp53 Arg72Pro SNP determines
neovascularization, brain repair and neurological recovery after ICH. This study is the first in which the Pro allele of Tp53 is linked
to vascular repair and ability to functionally recover from stroke.
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Non-traumatic intracerebral hemorrhage (ICH) is one of the
most devastating and disabling forms of stroke that account for
10–15% of all cases of stroke hospital admissions.1,2,3 The
average mortality rate was 50%, most of which occur during
the first days after stroke. Among survivors, only an estimated
20%will regain functional independence at 6months, whereas
more than one-third of affected patients will not survive the first
year.1,3 Unfortunately, prediction of functional outcome that
would assist in both preventive and therapeutic interventions
remains elusive.1,3
Functional outcome after ICH depends on the balance
between brain injury and the activation of yet unknown com-
pensatory response repairing the consequent damage.4,5
Recent evidences indicate that strategies to enhance the
response following brain injury provide promising opportu-
nities to improve clinical outcomes and brain repair.5 Then, to
develop effective therapies that promote brain repair, we must
have an understanding of the cellular and molecular events
involved in the recovery from an ischemic insult.
The adult brain vascular system is stable under normal
conditions and is activated in response to pathological
conditions including injury.6 Neovascularization following
stroke is an essential compensatory response mediating brain
repair, as it stimulates blood flow and metabolism in the
damaged area7,8 that activate other brain remodeling post-
stroke events leading to improved functional outcome of stroke
patients.9,10 Neovascularization requires new vessel forma-
tion from mature endothelial cells and immature CD34+
progenitor cells that includes endothelial progenitor cells
(EPCs). These progenitor cells are mobilized from the bone
marrow after vascular injury and home to the site of
neovascularization, contributing to regeneration by either
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direct incorporation into newly forming vascular structures or
indirectly via the secretion of proangiogenic growth factors,
thereby enhancing the overall vascular recovery of ischemic
brain.11–14 Furthermore, emerging evidences confer to circu-
lating EPC levels a prognostic value in the prediction of
functional outcome in ischemic stroke15–17 and ICH18 patients.
The human Tp53 gene harbors a common single-nucleotide
polymorphism (SNP) at codon 72, which yields an arginine-to-
proline amino-acidic substitution (Tp53 Arg72Pro SNP) that
modulates the apoptotic activity of the tumor suppressor
protein p53.19–22 Previously, we found that the Tp53 Arg72Pro
SNP controls neuronal susceptibility to ischemia-induced
apoptosis in vitro.23 In this study, we show that the Tp53
Arg72Pro SNP modulates endothelial cell survival after
experimental ICH in vivo, which promotes EPC mobilization
and neovascularization. Furthermore, functional recovery of
patients after ICH is conditioned by the Tp53 Arg72Pro
genotype. Our results thus reveal a novel function of the Tp53
Arg72Pro SNP in cerebrovascular repair and neurological
outcome after stroke.
Results
The Tp53 Pro allele is associated with high levels of
circulating CD34+ cells and good functional prognosis
after ICH. To assess whether the Tp53 Arg72Pro SNP is
associated with long-term (12 months) prognosis after ICH,
patients (see Table 1 for baseline characteristics) were
matched by functional outcome at discharge based on the
modified Rankin scale (mRS) scores24 (Table 2). We found
that homozygous Arg allele patients (referred as Arg patients)
with good outcome (mRS⩽ 2) at discharge suffered progres-
sive disability (mRS42) after ICH. In contrast, patients
harboring the Pro allele (referred as Pro patients) maintained
a favorable outcome, even at long term after ICH (Figure 1a).
Moreover, functional recovery was time-dependently
improved in the Pro patients who had poor functional
outcome (mRS42) at discharge, whereas it worsened in
the Arg patients (Figure 1b). Interestingly, although the lesion
volume on admission (Figure 1c) and perihematoma edema
volume at 48–72 h following ICH (Figure 1d) were similar in
both genotypes, indicating similar initial hemorrhagic
damage, a fourfold lower residual cavity volume was
observed in Pro patients at 6 months after ICH when
compared with Arg patients (Figure 1e). Taken together,
these results indicate that Tp53-codon 72 Pro allele-carrying
subjects are protected against long-term poor functional
outcome after ICH, whereas the homozygous Arg allele is
associated to poor prognosis.
To understand the mechanism responsible for the long-term
difference in prognosis of both alleles, we focused on
neovascularization, a late-onset process that facilitates the
neurogenesis, synaptogenesis and synaptic plasticity respon-
sible for the long-term repair of the ischemic brain.9
Neovascularization after cerebral ischemia is promoted by
circulating CD34+ progenitor cells11,13,14,25 and, although the
mechanism is unknown, it correlates with functional outcome
in ischemic stroke15–17 and ICH18 patients. We first corrobo-
rated this correlation in our ICH cohort (Figure 2a). Thus,
levels of circulating CD34+ progenitor increased in patients
with good functional outcome, whereas remained unchanged
in those with poor prognosis (Figure 2a). To elucidate whether
the Tp53 Arg72Pro SNP influenced neovascularization, we
next matched patients by genotype and determined the levels
of circulating CD34+ cells. As shown in Figure 2b, whilst levels
of CD34+ cells at admission were similar in both genotypes,
they significantly increased as soon as 7 days following ICH in
Pro, but not in Arg patients. Interestingly, the patients showing
the highest levels of CD34+ cells at 7 days after ICH
corresponded with the Pro genotype and good prognosis
(mR⩽2 at 3 months); in contrast, the patients with the lowest
CD34+ levels were those of the Arg genotype and poor
prognosis (mRS42 at 3 months) (Figure 2c). Flow cytometry
analysis of the CD34+ progenitor cells revealed that the
observed differences in CD34+ cell levels were not due to cell
survival changes (Figure 2d). Next, we analyzed vascular
endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and
stromal cell-derived factor-1α (SDF-1α) for their known roles in
Table 1 Baseline demographic and clinical features of patients
Variables ICH (n= 78)
Age (years) 70.4±11.1
Gender
Females, n (%) 24 (30.8)
Males, n (%) 54 (69.2)
Time from ICH onset (h) 5.1±3.7
Diagnosis
Etiologic
Hypertensive, n (%) 36 (46.2)
Amyloid, n (%) 26 (33.3)
Anticoagulants, n (%) 3 (3.8)
Undetermined, n (%) 13 (16.7)
Topographic
Deep, n (%) 48 (61.5)
Lobar, n (%) 30 (38.5)
Ventricular extension, n (%) 23 (29.5)
NIHSS on admission 10 [5, 16]
Lesion volume on admission (ml) 28.8±27.9
Residual lesion volume at 6 months (ml) 11.7±17.7
Poor prognosis at 3 months, n (%) 42 (53.8)
mRS at 3 months
0, n (%) 10 (12.8)
1, n (%) 17 (21.8)
2, n (%) 9 (11.5)
3, n (%) 12 (15.9)
4, n (%) 9 (11.5)
5, n (%) 3 (3.8)
6, n (%) 18 (23.1)
Tp53 Arg72Pro SNP
Pro (Arg/Pro+Pro/Pro), n (%) 31 (39.8)
Arg (Arg/Arg), n (%) 47 (60.2)
Circulating CD34+ progenitor cells
At admission, cells per 2.5 × 105 events 203.9±90.7
At day 7, cells per 2.5 × 105 events 359.9±138.4
Abbreviations: ICH, intracerebral hemorrhage; mRS, modified Rankin Scale;
NIHSS, National Institute of Health Stroke Scale; SNP, single-nucleotide
polymorphism.
Patients were admitted at the University Hospital of Santiago de Compostela
(Galicia, Spain). Data are shown as percentage (n, %), mean (S.D.) or medians
(quartiles).
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the activation and mobilization of progenitor cells from the
bone marrow in response to peripheral tissue hypoxia after
stroke,12,26 and migration of EPC to injured tissues8,27 to
promote neovascularization. Serum levels of VEGF
(Figure 1e), Ang-1 (Figure 1f) and SDF-1α (Figure 1g) were
significantly higher in Pro patients when compared with Arg
patients, at 72 h after ICH. Altogether, these data indicate that
the Tp53 Arg72Pro SNP determines the release of progenitor
cell-activating factors and EPC mobilization from the bone
marrow as a compensatory response to promote brain repair
and functional recovery after ICH in humans.
The p53 Pro variant increases endothelial cell survival
and triggers efficient EPC mobilization via VEGF and
SDF-1α leading to neovascularization after experimental
ICH. To investigate directly the impact of the Tp53 Arg72Pro
SNP on neovascularization after ICH, we next subjected
humanized Tp53 knock-in (KI) mice models of both Arg72Pro
codon variants28 to a previously validated experimental
ICH.29 As shown in Figures 3a and b, the lesion volume
observed at 6 h after experimental ICH was similar in both
genotypes, indicating similar initial hemorrhagic insult; how-
ever, the time-dependent decrease in lesion volume was
significantly faster in Pro than in Arg allele-carrying mice.
Next, we evaluated functional recovery of mice after ICH by
testing motor coordination and limb strength using the
accelerated rotarod test.30,31 Whereas at 24 h after ICH
motor impairment was similar in both genotypes, mice
expressing the Pro variant showed better motor performance
than those with the Arg variant at both 48 h and 7 days after
the hemorrhagic insult, which reflects a different level of
functional recovery. Furthermore, mice carrying the Pro allele
reached basal (before ICH) motor performance at 7 days
Table 2 Modified Rankin Scale
Grade Criteria
0 No symptoms at all
1 No significant disability: despite symptoms, able to carry
out all usual duties and activities
2 Slight disability: unable to perform all previous activities
but able to look after own affairs without assistance
3 Moderate disability: requiring some help but able to walk
without assistance
4 Moderately severe disability: unable to walk without
assistance and unable to attend to own bodily needs
without assistance
5 Severe disability: bedridden, incontinent and requiring
constant nursing care and attention
6 Death
Modified from Banks and Marotta24
Figure 1 The Tp53 Arg72Pro SNP modulates long-term functional outcome after ICH. Patients were admitted at the University Clinical Hospital of Santiago de Compostela
(Galicia, Spain). The study included 78 (Arg/Arg: 47, referred as Arg; Arg/Pro and Pro/Pro: 31, referred as Pro) patients with non-traumatic ICH. (a and b) Modified Rankin Scale
(mRS) was used to evaluate the functional outcome of ICH patients. Patients were matched by (a) good (mRS⩽ 2) and (b) poor (mRS42) functional outcome at discharge and
mRS scores were evaluated at 3 and 12 months after ICH with indicated Tp53 Arg72Pro genotypes. Boxplots show median values (horizontal line inside the box) and quartiles
(box boundaries) (Mann–Whitney test). (c) Lesion volume on admission, (d) perihematoma edema volume at 48–72 h after ICH, and (e) residual lesion volume at 6 months after
ICH were measured in patients with indicated Tp53 Arg72Pro genotypes. Data are mean±S.D. (Student’s t-test). **Po0.0001 versus Pro patients
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after ICH; however, this effect was not observed in the Arg
allele-carrying mice (Figure 3c), indicating poorer functional
recovery than the Pro mice. All these findings confirm the
results observed in humans (Figure 1), supporting that the
humanized Tp53 Arg72Pro SNP KI mice variants functionally
recapitulate the human phenotypes.
In vivo terminal deoxynucleotidyl transferase dUTP nick-
end labeling (TUNEL) staining revealed significantly less
apoptotic cell death in the perihematoma area in the mice
harboring the Pro allele than in those with the Arg allele
(Figure 3d). Among the affected cells, we found not only
neurons (TUNEL+ NeuN+ cells) (Figure 3e) but also endothe-
lial cells (TUNEL+ CD31+ cells) (Figure 3f), which both
underwent less apoptotic death in the Pro mice than in the
Arg one. In vitro ischemia (oxygen and glucose deprivation)
confirmed higher survival of cultured brain endothelial cells
obtained from the Pro mice (Figure 3g). We therefore
hypothesized whether endothelial cells’ survival against ICH
dictated the production and release of angiogenic and EPC-
mobilizing factors, including VEGF, Ang-1 and SDF-1α that led
to the EPCmobilization, cerebrovascular repair and functional
prognosis observed in patients (Figures 1a and 2e–g). To test
this, we measured circulating levels of CD34+ progenitor cells
in both the Tp53 Pro and Arg SNP variant KI mice after
experimental ICH. In good agreement with the data observed
in ICH patients (Figure 2b), the levels of CD34+ progenitor
cells were significantly higher in the Pro mice when compared
with the Arg one, 24 h after the insult (Figure 4a). Given that
CD34 is not exclusively present in EPC, but also on mature
endothelial cells – although at a lower level – specific EPC
identification should be demonstrated by showing the pre-
sence of the endothelial marker VEGF receptor-2 (VEGFR2)
and the absence of the pan-leukocyte marker CD45.12,16,32,33
We therefore analyzed CD34+/VEGFR2+/CD45− cells by
FACS as a bona fide marker of EPC. As shown in Figure 4b,
experimental ICH in the Tp53 Arg72Pro mice triggered a t
ime-dependent increase in the circulating levels of EPC
in the Pro allele-carrying mice, reaching the maximum level
at 24 h after the insult; however, this effect was significantly
attenuated in mice with the Arg allele (Figure 4b).
Such difference was not because of a putative differential
rate of EPC proliferation at the light of their same BrdU
Figure 2 The Tp53 Arg72Pro SNP dictates levels of circulating CD34+ progenitor cells after ICH. Patients were admitted at the University Clinical Hospital of Santiago de
Compostela (Galicia, Spain). The study included 78 (Arg/Arg: 47, referred as Arg; Arg/Pro and Pro/Pro: 31, referred as Pro) patients with non-traumatic ICH. (a) Levels of
circulating CD34+ progenitor cells in patients with good (mRS⩽ 2; 36 patients) and poor (mRS42; 42 patients) functional outcome at 3 months after ICH (one-way analysis of
variance (ANOVA) followed by Bonferroni’s test). (b) Patients were matched by genotype (Arg and Pro) and we studied circulating levels of CD34+ progenitor cells at 7 days after
ICH in relation to mRS scores at 3 months after ICH. (c) Levels of circulating CD34+ progenitor cells in patients with indicated Tp53 Arg72Pro genotypes (one-way ANOVA
followed by Bonferroni’s test). (d) Apoptosis (annexin V-APC-stained cells that were 7-AAD-negative) were determined in CD34+ progenitor cells by flow cytometry at day 7
following ICH. (g–i) Serum levels of (g) VEGF (pg/ml), (h) Ang-1 (ng/ml) and (i) SDF-1α (ng/ml) at 72 h after ICH with indicated Tp53 Arg72Pro genotypes (Student’s t-test). Data
are mean±S.D. *Po0.001; **Po0.0001 versus (a) good functional outcome or (b–g) Pro patients
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incorporation rate (Figure 4c) and cell cycle phase distribution
(Figure 4d) in both genotypes. Furthermore, levels of
EPC-mobilizing cytokines, VEGF (Figure 4e) and SDF-1α
(Figure 4f), sharply increased in the Pro mice after the
ICH insult, whereas this effect was significantly weakened in
the Arg mice. Altogether, these results strongly suggest
that the regulation of EPC mobilization by these
cytokines dictates the different functional outcomes
of the Tp53 Pro and Arg alleles in mice and patients
after ICH.
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As the ability of healthy endothelial to produce VEGF and
SDF-1α has been estimated to be several weeks after the
ischemic injury,7 it is conceivable to propose that the high
survival rate of endothelial cells in the Pro allele herein
described is a key factor determining long-lasting production
of growth factors and EPC mobilization after ICH. To ascertain
whether the Tp53 Arg72Pro SNP determined cerebral neovas-
cularization after ICH, brain sections of the KImicewere stained
with the vascular endothelial cell marker isolectin-B4 (IB4), a
well-known index of vascularization.34 As IB4 also labels
microglial cells,34 we first used a combination of IB4 with the
microglia-specific marker, Iba1. As shown in Figure 5a, we
found microglial cells (IB4+/Iba1+ cells) in the perihematoma
area in both Pro and Arg mice; however, microglia appears to
locate around vessels in mice carrying the Pro allele, but not in
those with the Arg one (Figure 5b), which may contribute to
remove cell debris10,35 andpromotevascular repair.36 In relation
to morphology, we found that endothelial cells (IB4+/Iba1− cells)
form tubular structures, whereas microglia (IB4+/Iba1+ cells)
exhibited a dendritic morphology in both Arg and Pro mice
(Figure 5). Furthermore, IB4 staining is more pronounced in
endothelial cells (Figure 5a). Therefore, IB4 labeling easily
allows distinguishing microglial cells from endothelial cells,
hence representing a suitable index of neovascularization as
described previously.34
We observed that experimental ICH induced a decrease in
IB4 staining in the perihematoma area, 24 h after the insult in
both Pro and Arg allele-carrying mice, suggesting brain blood
vessel disruption with endothelial cell loss (Figure 6a).
However, this effect was more pronounced in the Arg mice,
in good agreement with the higher apoptotic endothelial cell
death observed in this genotype (Figure 6a). Interestingly, the
vascular density increased in the Promice 7 days after ICH, as
revealed by the enhanced IB4 staining indicating vascular
repair; however, this effect was significantly attenuated in the
Arg mice (Figure 6a). We confirmed these observations using
the endothelial cell marker, CD31 (Figure 6b). Neovascular-
ization in the Pro allele-carrying mice was further confirmed as
judged by the new IB4+/Iba1− small vessels sprouting34 from
the existing vasculature (Figure 7). Our results thus demon-
strate that vascular repair after ICH is mainly restricted to the
Pro allele-carrying Tp53 Arg72Pro SNP.
Discussion
During the recovery of the ischemic brain, oxygen and nutrient
supply restoration is a critical process that requires the
Figure 3 The Pro SNP variant promotes survival of cerebral endothelial cells and functional recovery following ICH. Humanized knock-in mouse model for both codon
Arg72Pro variants of p53 (Pro and Arg) were subjected to experimental ICH. (a) Lesion volume (mm3) was measured on Nissl-stained histological sections from whole brain at
indicated time points (one-way analysis of variance (ANOVA) followed by Bonferroni’s test; n= 4–5 mice per group). (b) Representative images of Nissl-stained histological
sections from whole brain at indicated time points after ICH. (c) Rotarod testing was performed in mice before (basal) and at indicated time points after ICH. Latency to fall off the
rotarod was recorded (one-way ANOVA followed by Bonferroni’s test; n= 4–5 mice per group). (d) Cell apoptosis were determined in the perihematoma brain region by TUNEL
assay. Apoptotic cells were quantified as TUNEL (red)-positive cells per mm2 at 24 h following ICH (Student’s t-test; n= 4–5 mice per group). (e) Neuronal apoptosis were
identified in perihematoma brain region by double staining with TUNEL (red) and neuronal marker NeuN (green) at 24 h after ICH (Student’s t-test; n= 4–5 mice per group).
Representative images are shown. (f) Apoptotic endothelial cells were identified in perihematoma brain region by double staining with TUNEL (red) and endothelial cell marker
CD31 (green) at 24 h after ICH. (g) Brain endothelial cells in primary culture were exposed to oxygen and glucose deprivation during 1, 3 and 6 h, and apoptosis were determined
by flow cytometry (one-way ANOVA followed by Bonferroni’s test; n= 3 cell cultures per condition). Data are mean± S.E.M. *Po0.05 versus Pro
Figure 4 The Pro SNP variant promotes efficient EPC mobilization via VEGFand
SDF-1α following ICH. Humanized knock-in mouse model for both codon Arg72Pro
variants of p53 (Pro and Arg) were subjected to experimental ICH. (a) Levels of
circulating CD34+ progenitor cells were determined by flow cytometry at 24 h after
experimental ICH. Data are mean±S.E.M. (Student’s t-test; n= 3 mice per group).
(b) Levels of circulating CD34+/CD45−/VEGFR2+ cells were determined by
flow cytometry at indicated time points after ICH. (c and d) CD34+ cells obtained
from bone marrow of Pro and Arg mice were incubated during 3 h with BrdU
(1 mM). (c) BrdU incorporation and (d) cell cycle distribution were determined
by flow cytometry. Data are mean±S.E.M. (n= 3 mice per group). Serum levels of
(e) VEGF (pg/ml) and (f) SDF-1α (ng/ml) were measured at different time points
after ICH (basal: 24 h before ICH). Data are mean± S.E.M. (one-way analysis of
variance (ANOVA) followed by Bonferroni’s test; n= 4–6 mice per group). *Po0.05
versus Pro
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neovascularization of the affected area, where it stimulates the
blood flow and metabolism7,8 to induce poststroke brain
remodeling and improved functional outcome.9,10 In this study,
we describe that the Tp53 Arg72Pro SNP dictates functional
prognosis after ICH through a mechanism that involves
endogenous bone marrow-derived EPC mobilization leading
to neovascularization.
Delayed revascularization of postischemic brain tissue is
known to be themain obstacle to preserve the brain function in
stroke and ischemic retinopathies.37,38 Here, we found that the
patients harboring the Arg allele show delayed neovascular-
ization, and poor functional outcome after ICH, when
compared with the Pro allele carriers. Neovascularization not
only augments cerebral flow,7,8 but also migration of macro-
phages to the ischemic area to rapidly remove the necrotic
debris.10,35 Consequently, the increase in the number of newly
formed vessels correlates with long-term survival of stroke
patients.10 Noticeably, our data show that the Pro allele is
associated with increased neovascularization and good long-
term functional outcome and survival after ICH.
Progenitor cell mobilization from the bone marrow occurs
via the production and release of angiogenic factors, such as
VEGF and Ang-1, in response to the peripheral tissue hypoxia
after stroke.12,26 Moreover, VEGF and the chemokine SDF-1α
promote the migration and homing of EPC to the injured
tissues, favor EPC differentiation and activate mature
endothelial cells during neovascularization.8,27 The higher
levels of VEGF and SDF-1α, which we found after ICH in Pro
allele-carrying patients, thus reflects an efficient mobilization
and recruitment of CD34+ progenitor cells – including EPC –
from the bonemarrow to the sites of vascular injury. Besides its
direct contribution to the formation of new vessels, recruited
progenitor cells to the ischemic brain tissuemay also remain in
the interstitial space, whereby secreting cytokines and growth
factors – for example, SDF-1α and VEGF – indirectly promote
vascular repair via paracrine mechanisms.12,26 In addition, it
has been described that SDF-1α, released from infarcted brain
tissue, together with EPC, operates as a chemotactic factor for
the recruitment of additional EPC.7,39 Our data are therefore
consistent with the notion that this pathway is stimulated in the
Pro allele patients leading to improved vascular repair, brain
recovery and good functional prognosis after ICH.
To understand the mechanism responsible for the different
postischemic neovascularization in Arg and Pro alleles, we
focused on our previous data showing that the Tp53 Arg72Pro
SNP modulates neuronal survival after ischemia in vitro,23
which we now confirm in vivo (this work). Interestingly, besides
neurons, the reduced vulnerability to ICH-induced apoptosis is
also observed in the endothelial cells of Pro allele patients.
Accordingly, healthier endothelial cells, such as those of the
Pro patients, will likely produce more VEGF and SDF-1α for
longer periods after ischemic injury as shown previously,7
hence improving neovascularization. As the long-term predic-
tion of functional outcome has remained elusive,2 our results
shed light on the long-term survival determinants of ICH
patients.
In conclusion, here we show that different prognosis after
ICH is dictated by the Tp53 Arg72Pro SNP through a
mechanism that involves endogenous bone marrow-derived
EPC mobilization leading to neovascularization, brain repair
and improved functional prognosis after stroke. This study is
the first in which the Pro allele of Tp53 is linked to
Figure 5 The Pro SNP variant promotes microglia localization around vessels after ICH. (a and b) Humanized knock-in mouse model for both codon Arg72Pro variants of p53
(Pro and Arg) were subjected to experimental ICH. Brain sections were costained with the vascular endothelial cell marker IB4 and the microglia-specific marker Iba1 at day 7
after experimental ICH. Nuclei were stained with the far-red fluorescent specific DNA dye TO-PRO3
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angiogenesis and ability to recover functionally from stroke.
Thus, we propose that the Tp53 Arg72Pro SNP analysis
should be used for the stratification of patients in clinical trials
aimed to predict the functional prognosis after ICH. Further-
more, whether the mechanism herein described is also
involved in the prognosis of other pathological conditions,
such as cancer or chronic inflammation including retinopa-
thies, is a likely possibility deserving further investigation.
Therapies aimed to enhance the levels of cytokine-mediated
EPC mobilization leading to neovascularization may be
considered to improve the functional prognosis of Arg-allele-
carrying ICH patients.
Material and Methods
Patients. Ninety-six consecutive patients with a first-ever primary non-traumatic
ICH ofo12 h from symptoms onset and previously independent for their daily living
activities were prospectively included in the study between March 2011 and
February 2013. Patients with previously altered functional capacity (mRS⩾ 1)
(n= 4), chronic inflammatory diseases (n= 3), severe hepatic (n= 3) or renal
(n= 2) diseases, cancer (n= 2) or infectious disease in the 15 days before
inclusion (n= 1) were excluded. Furthermore, three patients did not accept their
participation in the study, thus a total of 78 patients (male, 69.2%; mean age,
70.4± 11.1 years) were finally included in the study.
This research was carried out in accordance with the Declaration of Helsinki of the
World Medical Association (2008) and approved by the Ethics Committee of the
Servizo Galego de Saúde. Informed consent was obtained from each patient or their
relatives after full explanation of the procedures.
All patients were admitted to an acute stroke unit and treated according to the
guidelines of the Cerebrovascular Diseases Study Group of the Spanish Society of
Neurology.40 Etiological diagnosis was made according the Guidelines for the
management of spontaneous ICH in adults from the American Heart Association/
American Stroke Association Stroke Council, High Blood Pressure Research Council
and the Quality of Care and Outcomes in Research Interdisciplinary Working
Group.41 Medical history recording potential vascular risk factors, blood and
Figure 6 Neovascularization after ICH is conditioned by the Tp53 Arg72Pro SNP. Humanized knock-in mouse model for both codon Arg72Pro variants of p53 (Pro and Arg)
were subjected to experimental ICH. (a) Brain sections were stained with the vascular endothelial cell marker IB4 and the far-red fluorescent nuclear dye TO-PRO3 before and
after 24 h and 7 days after ICH. (b) Brain sections were stained with the vascular endothelial cell marker CD31 at day 7 following experimental ICH. Green (CD31) fluorescence
area per field was determined using the NIH ImageJ version 1.48 software (NIH, Bethesda, MD, USA). Data are mean± S.E.M. (Student’s t-test; n= 4 mice per group). *Po0.05
versus Pro
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coagulation tests, 12-lead ECG and chest radiography were performed at admission.
To evaluate neurologic deficit, the National Institute of Health Stroke Scale (NIHSS)
was performed at admission. Functional outcome was evaluated at discharge and at
3 and 12 months by using the mRS. NIHSS and mRS were evaluated by
internationally certified neurologists.23,24 The main outcome variable for all patients
was considered poor functional prognosis (mRS42) at 3 months± 15 days.
Antihypertensive treatment with intravenous labetalol or urapidil was administered
in case of systolic blood pressure 4185 mm Hg or diastolic blood pressure
4105 mm Hg. Low-dose subcutaneous heparin was used for the prevention of deep
vein thrombosis and pulmonary thromboembolism.
Neuroimaging studies. Lesion volumes of the intracerebral hemorrhagic
patients were determined by computed tomography (CT) scan using the formula
0.5 × a × b × c, where a and b represent the largest perpendicular diameters, and c
represents the slice thickness. The hematoma volume was determined upon
admission, and the perihematoma edema volume (total volume minus hematoma
volume) in a second CT performed after 48–72 h. The residual cavity volume was
determined with CT at 6 months± 15 days. ICH topography was classified as lobar
when it mainly affected the cortical or subcortical white matter of the cerebral lobes
or as deep when it was limited to the internal capsule, the basal ganglia or
thalamus. The presence of ventricular extension of the hematoma was also
recorded. All neuroimaging evaluations were performed by neuroradiologists blinded
to the patients’ clinical and laboratory results.
Human Tp53 polymorphism analysis. Genotyping of human Tp53
polymorphism was performed at the University of Salamanca by authors blinded to
the clinical status of patients, by using the PCR-RFLP technique.23 The Tp53 SNP
of exon 4 at codon 72 (Arg72Pro; rs1042522) was detected by amplifying genomic
DNA with the forward primer 5′-TCTACAGTCCCCCTTGCCGT-3′ and the reverse
primer 5′-CTGACCGTGCAAGTCACAGA-3′. Tp53 exon 4, where BstU1 (Bsh1236I)
RFLP is located, was amplified within a 298-bp DNA fragment. Digests were
separated on agarose gel (3%) and the Midori Green Advanced-stained DNA
fragments (Nippon Genetics Europe GmbH, Düren, Germany) were analyzed under
a UV source (Gel Imager System; Bio-Rad, Hercules, CA, USA). The distribution of
genotype frequencies in Arg72Pro between the ICH cohort was within the
Hardy–Weinberg equilibrium (P40.1 in all cases). As the Pro allele is likely to exert
a dominant effect on the Arg one,23 two groups were considered for this study: Pro
(Pro/Pro and Pro/Arg genotypes) and Arg (Arg/Arg genotype) patients.
Animals. The humanized Tp53 Arg72Pro KI mice were generously donated by
Prof. DG Johnson (The University of Texas MD Anderson Cancer Center, Smithville,
TX, USA).28 Animals were bred at the Animal Experimentation Service of the
University of Salamanca, in accordance with Spanish legislation (RD 53/2013).
Protocols were approved by the Bioethics Committee of the Institute of Biomedical
Research of Salamanca. All efforts were made to minimize the number of animals
used and ensure minimal suffering. All studies described below were conducted in a
blind manner.
Experimental model of ICH. Experimental ICH was induced in 12-week-old
mice by injecting bacterial collagenase VII from Clostridium histolyticum (purified by
chromatography; Sigma, Madrid, Spain) into the basal ganglia.29 Briefly, male mice
under sevoflurane anesthesia (4% for induction and 3% for maintenance)
evaporated in an oxygen–air mixture (30–70%) were placed in a stereotaxic frame
(model no. 1900; Kopf, Tujunga, CA, USA) with a digital coordinate readout system
(Wizard 550 Readouts; Anilam, Schaumburg, IL, USA). Collagenase (0.1 U in 0.5 μl
of saline) was injected unilaterally into the striatum using stereotactic coordinates:
+0.9 mm anterior and +2.0 mm lateral to bregma, to a depth of 3.5 mm and at a
rate of 0.1 μl/min over 5 min. The needle stayed in place for additional 10 min to
prevent reflux. During the procedure, rectal temperature was monitored (BAT-12
thermometer; Physitemp, Clifton, NJ, USA) and maintained at 37± 0.5 °C. After the
surgery, the animals were placed in a warm environment for recovering. Lesion
volume was calculated from serial Nissl-stained sections of the mouse brains at 6 h
and 1, 7 and 14 days after collagenase injection.
Accelerated rotarod test. Performance based on motor coordination and
limb strength in this test was assessed before (basal) and after ICH. Mice were
trained for 3 days before ICH. All determinations were carried out at the same time
every testing session by a researcher blind to the genotype. Mice were allowed to
Figure 7 The Pro SNP variant promotes vessel formation after ICH. Humanized knock-in mouse model carrying the Pro SNP variant of p53 were subjected to experimental
ICH. Brain sections were costained with the vascular endothelial cell marker IB4 and the microglia-specific marker Iba1 at day 7 after experimental ICH. Nuclei were stained with
the far-red fluorescent specific DNA dye TO-PRO3. White arrow indicates newly formed vessels
Tp53 ArgPro SNP dictates vascularization after ICH
C Rodríguez et al
152
Cell Death and Differentiation
stay for 300 s on a five-lane accelerating rotarod (Model 47600; Ugo Basile,
Comerio, Italy) rotating rod with a continuous accelerating rotation speed from 4 to
40 r.p.m., increasing 4 r.p.m. every 30 s and reaching the final speed at 270 s. The
latency to fall off the rotarod was measured during this period, annotating the time
the animal stayed on the rotation rod. Data from tests in which animals completed
three turns without walking were disregarded.42
Flow cytometry analysis of circulating progenitor cell levels. A
7 ml sample of EDTA venous blood was obtained from ICH patients at admission
and day 7± 1. Samples were processed within 1 h after collection by one
researcher who had no knowledge of the patients’ clinical and radiological results.
Mononuclear cells were isolated from peripheral blood by Ficoll density gradient
centrifugation suspended in 100 ml of PBS. Immunofluorescence cell staining was
performed in triplicate with the fluorescent conjugated antibody CD34-Fluorescein
isothiocyanate (FITC; Becton Dickinson, Bergen, NJ, USA). IgG1-FITC antibody
(Becton Dickinson) served as a negative control. Fluorescence was measured
immediately after staining by flow cytometry (BD FACSAria IIu Becton Dickinson).
Number of human CD34+ progenitor cells was expressed as absolute cell counts
obtained after the measurement of 2.5 × 105 events in the lymphocyte gate (FACS
Diva software; BD Biosciences, Bergen, NJ, USA).18 In some experiments, following
CD34-FITC staining, cells were stained with annexin V-allophycocyanin (APC) and
7-aminoactinomycin D (7-AAD) in binding buffer (100 mM HEPES, 140 mM NaCl
and 2.5 mM CaCl2). CD34
+ progenitor cells (identified by FITC fluorescence) were
analyzed, and the annexin V-APC-stained cells that were 7-AAD-negative were
considered to be apoptotic.23,43
In the Arg72Pro p53 KI mice, blood samples were collected in EDTA-coated
microtainer tubes (Becton Dickinson) at 24 h before surgery (basal) and at different
time points following experimental ICH. Immunofluorescence cell staining was
performed in triplicate with the fluorescent conjugated antibodies CD34-FITC,
VEGFR2-APC (eBioscience, San Diego, CA, USA) and CD45-phycoerythrin (PE;
Immunostep, Salamanca, Spain). Cell fluorescence was measured immediately after
staining by flow cytometry.12 Percentage of CD34+/VEGFR2+/CD45− cells was
calculated using the CellQuest software (BD Biosciences).
Measurement of VEGF, Ang-1 and SDF-1α serum levels. Blood
samples were obtained from ICH patients at 72± 24 h following ICH, and from
Arg72Pro p53 KI mice at different time points after collagenase injection. Samples
were centrifuged at 3000 × g for 10 min and immediately frozen and stored at
− 80 °C. Serum levels of VEGF, Ang-1 and SDF-1α were measured using
commercially available quantitative ELISA (enzyme-linked immunosorbent assay)
Kits (VEGF and Ang-1 (R&D Systems Inc, Minneapolis, MN, USA) and SDF-1α
(RayBiotech Inc., Norcross, GA, USA and Abcam, Cambridge, UK)).18 Intra- and
interassay coefficients were o8% for all markers.
Cell cultures and treatments. Primary cultures of mouse brain capillary
endothelial cell were prepared from cerebral cortices of 3-week-old Arg72Pro p53
KI mice.44 Cortices were isolated, chopped in Dulbecco’s modified Eagle’s medium
(DMEM), and homogenized with a serological pipette. Homogenates were cleaned
from myelin using a 20% (w/v) BSA in DMEM and separated from erythrocytes by
two centrifugations at 1000 × g, for 15 min. The resulting suspension was digested
in 0.02 mg/ml collagenase/dispase (Roche, Heidelberg, Germany) in DMEM
supplemented with 0.04 mg/ml DNase I (Roche), for 1 h at 37 °C in a shaking water
bath. Cells were seeded on plastic plates coated with collagen I (BD Biosciences)
and incubated in endothelial cell growth medium MV2 (Ready-to-use; Promocell,
Birmingham, UK) supplemented with L-glutamine (Lonza, Barcelona, Spain) and
3 μg/ml puromycin (Sigma). Brain endothelial cells were exposed to oxygen and
glucose deprivation45 and were stained with annexin V-APC and 7-AAD in binding
buffer to determine quantitatively the percentage of apoptotic cells (V-APC+/7-
AAD−) by flow cytometry.23,43
For isolation of bone marrow progenitor cells from Arg72Pro p53 KI mice,
whole bone marrow was collected from bilateral femurs and passed through a 40 μm
cell strainer (BD Falcon, BD Biosciences). Cells were then seeded on fibronectin-
coated plates and cultured in RPMI-1640 medium (Sigma) supplemented with 10%
(v/v) FBS. Cells were stained with CD34-FITC and BrdU incorporation and cell cycle
phase distribution analysis were performed by flow cytometry, using the APC BrdU
Flow Kit (BD Biosciences). BrdU+ cells and cell cycle distribution was measured
immediately after staining in the CD34+ cell population, by flow cytometry.43
Immunohistochemistry. Arg72Pro p53 KI mice were anesthetized by
intraperitoneal injection of a mixture (1:4) of xilacine hydrochloride (Bayer;
Leverkusen, Germany) and ketamine hydrochloride/chlorbutol (Merial; Lyon,
France), using 1 ml of the mixture per kg of body weight, and then perfused
intra-aortically with 0.9% NaCl, followed by 5 ml/g per body weight of Somogy’s
fixative (4% p/v paraformaldehyde, 0.2% p/v picric acid in 0.1 M phosphate buffer,
pH 7.4). After perfusion, brains were dissected out coronally in three parts and
postfixed, using the Somogy’s fixative, for overnight at 4 °C. Brain blocks were
rinsed with 0.1 M phosphate buffer and sequentially immersed in 10%, 20% and
30% (w/v) sucrose in phosphate buffer until they sank. After cryoprotection, 20-μm-
thick coronal sections were obtained with a freezing-sliding cryostate (Leica CM
1950 AgProtect; Leica Microsystems, Wetzlar, Germany). Coronal sections were
rinsed in 0.1 M PB three times each for 10 min and then incubated in (i) 1 : 250
anti-mouse CD31 (550274; BD Pharmingen, BD Biosciences), 1 : 200 anti-Iba1
(019-19741; Wako, Chemicals, Neuss, Germany), 1 : 1000 anti-NeuN (MAB377;
Merck Millipore, Bellerica, MA, USA) or 1 : 50 anti-IB4 (L2140; Sigma) in 0.2%
Triton X-100 (Sigma) and 5% goat serum (Jackson Immoresearch Laboratories,
West Grove, PA, USA) for 72 h at 4 °°C in 0.1 M PB; (ii) fluorophore-conjugated
secondary antibodies (Jackson Immunoresearch Laboratories) in 0.05% Triton
X-100 and 2% goat serum in 0.1 M phosphate buffer, for 2 h at room temperature.42
Nuclei were stained either with 6-diamidino-2-phenylindole (DAPI, blue fluo-
rescence; Sigma D9542) or the commercial monomeric cyanine nucleic acid stain
TO-PRO3 (far-red fluorescence; Molecular Probes T3605, Invitrogen) for 10 min.
After rinsing with PBS, sections were mounted with Fluoromount (Sigma) aqueous
mounting medium. Sections were examined with epifluorescence and appropriated
filters sets using a microscope (Nikon Inverted microscope Eclipse Ti-E; Nikon,
Tokyo, Japan) equipped with a precentered fiber illuminator (Nikon Intensilight
C-HGFI, Tokyo, Japan) and B/W CCD digital camera (Hamamatsu; Tokyo, Japan),
or with a spectral laser confocal microscope (Leica TSC-SL; Leica Microsystems)
with three lasers: multiline Argon (488 nm), Helium-Neon (543 nm) and Helium-
Neon (633 nm), and equipped with × 40, × 63 (1.4) HCX PL Apo oil immersion
objectives for high-resolution imaging. Quantifications were performed in three
regions of interest from three different sections per animal in an epifluorescence/
light microscope (Nikon, Tokyo, Japan). Area occupied by CD31+ vessels was
estimated by using the NIH image-processing package ImageJ (ImageJ 1.48v).
TUNEL assay. TUNEL assay was performed in brain sections following the
manufacturer’s protocol (Roche Diagnostics, Heidelberg, Germany). Brain sections,
fixed as above, were preincubated in TUNEL buffer containing 1 mM CoCl2,
140 mM sodium cacodylate and 0.3% Triton X-100 in 30 mM Tris buffer, pH 7.2, for
30 min. After incubation at 37 °C with the TUNEL reaction mixture containing
terminal deoxynucleotidyl transferase (800 /ml) and nucleotide mixture (1 μM) for
90 min, sections were rinsed with PBS and counterstained with Cy3-streptavidin
(Jackson Immunoresearch Laboratories).42
Statistics. Clinical results are expressed as either the mean±S.D. or median
(25th and 75th percentiles) for the continuous variables depending on whether or
not the data followed a normal distribution, respectively. The Kolmogorov–Smirnov
test was used for testing the normality of the distribution. The Student’s t-test
(normal data) or the Mann–Whitney test (non-normal data) was used to compare
continuous variables between two groups. Experimental results are expressed as
mean±S.E.M. A one-way ANOVA with a least significant difference post hoc test
was used to compare mean values between multiple groups, and a two-tailed,
unpaired Student’s t-test was used for two-group comparisons. In all instances,
Po0.05 were considered significant. Statistical analyses were performed using
SPSS Statistics 22.0 for Macintosh (IBM, Madrid, Spain).
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